Imel Biotherapeutics is developing a mitochondrial replacement therapy that enhances T cell functionality by replacing dysfunctional mitochondria with healthy ones, achieving over 90% mitochondrial replacement. This approach targets T cell exhaustion in elderly cancer patients, improving their immune response and potential treatment outcomes.
Funding
$15.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Elderly cancer patients often experience T cell exhaustion, which diminishes their immune response and reduces the effectiveness of treatments like checkpoint inhibitors. This exhaustion is linked to mitochondrial dysfunction within T cells, hindering their ability to effectively fight tumors. Current therapies struggle to overcome this T cell exhaustion in the elderly population, creating a need for innovative solutions.
Solution
Imel Biotherapeutics is developing a cell-based therapy that enhances T cell functionality by replacing dysfunctional mitochondria with healthy, functional mitochondria. Their mitochondrial replacement (MirC) process achieves a high rate of mitochondrial replacement, exceeding 90%. By restoring mitochondrial function, the therapy aims to revert T cell exhaustion, enabling the reprogrammed T cells to regain functionality, persist, and self-renew. The resulting autologous mitochondria-replaced T cells (Mir T Cells) are intravenously infused to reprogram aged immune cells and restore cellular functionality with enhanced agonist activation capacity. This approach has the potential to improve existing T cell-based therapies for solid tumor indications and address a wide range of age-associated conditions.
Target Audience
The primary target audience includes elderly cancer patients experiencing T cell exhaustion and resistance to checkpoint inhibitors, as well as clinicians seeking to improve the efficacy of cell-based immunotherapies.
Features
- Proprietary mitochondrial replacement (MirC) technology achieving >90% replacement of dysfunctional mitochondria in T cells.
- Autologous cell-based therapy using patient's own cells to minimize risk of rejection.
- Intravenous infusion of mitochondria-replaced T cells (Mir T Cells) to reprogram aged immune cells.
- Enhanced agonist activation capacity of reprogrammed T cells.
- Potential application to improve existing T cell-based therapies in solid tumor indications.
- Applicability to a wide range of age-associated indications beyond cancer.